Teva generic fish oil pill win ruffles Amarin investors

Amarin investors were slightly worried on 8 April after Teva revealed it had gained FDA approval of a generic version of GlaxoSmithKline's Lovaza (omega-3-acid ethyl esters), which is likely to make the market even more competitive for Amarin's fish oil pill Vascepa, which already is struggling to gain a foothold.